Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda for Refractory Atypical and Anaplastic Meningioma
NCT03016091Phase 2Terminated
- Sponsor
- Rabin Medical Center
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in atypical meningioma, anaplastic meningioma, hemangiopericytoma (HPC), sponsored by Rabin Medical Center. Started Jan 2018; status: terminated.
02
Drugs
03
Conditions
atypical meningiomaanaplastic meningiomahemangiopericytoma (HPC)
Beyond the preview
Go deeper on NCT03016091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016091.